Chronic paroxysmal hemicrania

Last updated
Chronic paroxysmal hemicrania
Other namesSjaastad syndrome
Specialty Neurology

Chronic paroxysmal hemicrania (CPH) is a severe debilitating unilateral headache usually affecting the area around the eye. It normally consists of multiple severe, yet short, headache attacks affecting only one side of the cranium. It is more commonly diagnosed in women than in men, but, unlike a migraine, has no neurological symptoms associated with it. CPH headaches are treated through the use of non-steroidal anti-inflammatory drugs, with indomethacin found to be usually effective in eliminating symptoms.

Contents

Paroxysmal hemicrania is classified by the characteristic (high) frequency and (short) duration of attacks experienced by patients that is somewhat similar to cluster headaches, despite some important differences explained below. [1] Episodic paroxysmal hemicrania attacks occur at least twice a year and last anywhere from seven days to a year with pain free periods of a month or longer separating them. Chronic paroxysmal hemicrania attacks occur over the course of more than a year without remission or with remissions lasting less than a month. [2]

Signs and symptoms

Individuals with CPH suffer multiple short, severe headaches a day, often more than five, with most lasting between 5 and 30 minutes each. When compared to cluster headaches, CPH attacks are typically shorter. [3] Each headache is centered around the eye, temple and forehead and is localized to one side of the head. While redness and watering of the eye are associated with CPH, patients typically do not experience nausea or vomiting. [4] Although less common, CPH may also present as severe unilateral ear pain accompanied by autonomic symptoms. [5] Autonomic symptoms may include the presence of red ear syndrome. [6]

Attacks hit the patient many times a day, from 5 times a day up to 40 times a day with an average of 11 a day. Mild background pain can persist between attacks. They come in bouts that last from 7 days to 1 year separated by remission periods that can last more than 3 months in episodic patients, or less than 3 months in chronic patients. Onset is in adulthood and the disorder may last indefinitely or spontaneously go into remission. Circadian mechanisms are likely involved in paroxysmal hemicrania due to its highly cyclic nature. No particular circannual recurrence characterizes symptomatic periods, although some patients can experience a seasonal preponderance. [1]

Causes

The causes of paroxysmal hemicrania are ultimately still unknown. Sympathetic symptoms such as miosis and ptosis might be linked with a generalized sympathetic dysfunction. Neuropathic mechanisms may be involved, since attacks can be triggered by mechanical stimulation. Perivascular neurogenic inflammatory processes can worsen symptoms or increase pain. Dilated blood vessels may contribute in stimulating trigeminal nociceptors directly, although they cannot be the origin of pain, since even suppression of vasodilation does not stop it once it’s started. [1]

Many secondary conditions have been reported to be possible causes of CPH, according to Mehta et al., most of which are arterial abrasions or tumors. These include aneurysms in the circle of Willis, middle cerebral artery infarction, parietal arteriovenous malformation, cavernous sinus and petrous ridge meningiomas, pituitary adenoma, Pancoast tumor, gangliocytoma of the sella turcica, and malignant frontal tumors. [7] This accentuates the urgency for those diagnosed with CPH to receive an MRI head scan.[ citation needed ]

Diagnosis

The temporal branch of the facial nerve is immediately above the eye. Cranial nerve VII.svg
The temporal branch of the facial nerve is immediately above the eye.

CPH is a long-term disease with symptoms lasting for longer than a year, either without remission or with remissions that last less than a month. [2] In order to be diagnosed with CPH, a patient needs to have had at least 20 attacks filling the following criteria: [ citation needed ]

In addition, diagnosis of CPH requires that neuropathy of the supraorbital area in the temporal branch of the facial nerve be ruled out. [9]

Comparison to cluster headaches

Though outwardly similar to cluster headaches, chronic paroxysmal hemicrania is rather different, and the two headaches are not a subset of one or the other. Key differences include:

Treatments

A ten-patient study conducted by Pareja et al. found that all patients diagnosed with CPH were responsive to indomethacin and were able to completely control their symptoms. Doses of the drug ranged from 25 mg per day to 150 mg per day with a median dose of 75 mg per 24-hour period. [10] Almost all cases of CPH respond positively and effectively to indometacin, but as much as 25 percent of patients discontinued use of the drug due to adverse side effects, namely complications in the gastrointestinal tract. [11] According to a case study by Milanlioglu et al., 100 mg of lamotrigine, an antiepileptic drug, administered twice daily alleviated all painful symptoms. No side effects were noted after two months of treatment. Dosage of lamotrigine was decreased to 50 mg a day after the first two months, and no symptoms or side-effects were recorded after a three-month followup. [12]

Use of topiramate has also been found to be an effective treatment for CPH, but cluster headache medications have been found to have little effect. [9]

Epidemiology

Although CPH is often compared to cluster headaches, it is much less prevalent, occurring in only 1–3% of those who experience cluster headaches. CPH occurs roughly in 1 in 50,000 people, while cluster headaches are comparatively more common and are found in 1 in 1000 people. [2] Cluster headaches occur primarily in men, while CPH is more commonly diagnosed in women. [3] The female to male ratio of diagnosed patients can range anywhere from 1.6:1 to 2.36:1. [2] Symptoms may begin to appear at any age, but onset usually occurs in adulthood with a mean starting age within the thirties. [8] [13]

History

CPH was discovered by Norwegians Ottar Sjaastad and Inge Dale in 1974. The term chronic paroxysmal hemicrania was first used in 1976 by Sjaastad to describe a condition seen in two of their patients who were experiencing repeated solitary and limited daily headache attacks on only one side of the cranium. [14]

It is possible that chronic paroxysmal hemicrania was first described by Johann Oppermann in 1747 under the term "hemicranias horologica". Oppermann's report included a 35-year-old woman who had hemicranial pain that lasted for 15 minutes and recurred regularly every hour. [3]

CPH has been included in the International Headache Society's classification system since 1988. [14]

See also

Related Research Articles

<span class="mw-page-title-main">Headache</span> Pain in the head, neck, or face

Headache, also known as cephalalgia, is the symptom of pain in the face, head, or neck. It can occur as a migraine, tension-type headache, or cluster headache. There is an increased risk of depression in those with severe headaches.

<span class="mw-page-title-main">Cluster headache</span> Neurological disorder

Cluster headache (CH) is a neurological disorder characterized by recurrent severe headaches on one side of the head, typically around the eye(s). There is often accompanying eye watering, nasal congestion, or swelling around the eye on the affected side. These symptoms typically last 15 minutes to 3 hours. Attacks often occur in clusters which typically last for weeks or months and occasionally more than a year.

<span class="mw-page-title-main">Tension headache</span> Medical condition

Tension headache, stress headache, or tension-type headache (TTH), is the most common type of primary headache. The pain usually radiates from the lower back of the head, the neck, eyes or other muscle groups in the body typically affecting both sides of the head. Tension-type headaches account for nearly 90% of all headaches.

A medication overuse headache (MOH), also known as a rebound headache, usually occurs when painkillers are taken frequently to relieve headaches. These cases are often referred to as painkiller headaches. Rebound headaches frequently occur daily, can be very painful and are a common cause of chronic daily headache. They typically occur in patients with an underlying headache disorder such as migraine or tension-type headache that "transforms" over time from an episodic condition to chronic daily headache due to excessive intake of acute headache relief medications. MOH is a serious, disabling and well-characterized disorder, which represents a worldwide problem and is now considered the third-most prevalent type of headache. The proportion of patients in the population with Chronic Daily Headache (CDH) who overuse acute medications ranges from 18% to 33%. The prevalence of medication overuse headache (MOH) varies depending on the population studied and diagnostic criteria used. However, it is estimated that MOH affects approximately 1-2% of the general population, but its relative frequency is much higher in secondary and tertiary care.

A headache is often present in patients with epilepsy. If the headache occurs in the vicinity of a seizure, it is defined as peri-ictal headache, which can occur either before (pre-ictal) or after (post-ictal) the seizure, to which the term ictal refers. An ictal headache itself may or may not be an epileptic manifestation. In the first case it is defined as ictal epileptic headache or simply epileptic headache. It is a real painful seizure, that can remain isolated or be followed by other manifestations of the seizure. On the other hand, the ictal non-epileptic headache is a headache that occurs during a seizure but it is not due to an epileptic mechanism. When the headache does not occur in the vicinity of a seizure it is defined as inter-ictal headache. In this case it is a disorder autonomous from epilepsy, that is a comorbidity.

<span class="mw-page-title-main">Indometacin</span> Anti-inflammatory drug

Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.

Occipital neuralgia (ON) is a painful condition affecting the posterior head in the distributions of the greater occipital nerve (GON), lesser occipital nerve (LON), third occipital nerve (TON), or a combination of the three. It is paroxysmal, lasting from seconds to minutes, and often consists of lancinating pain that directly results from the pathology of one of these nerves. It is paramount that physicians understand the differential diagnosis for this condition and specific diagnostic criteria. There are multiple treatment modalities, several of which have well-established efficacy in treating this condition.

Hemicrania continua (HC) is a persistent unilateral headache that responds to indomethacin. It is usually unremitting, but rare cases of remission have been documented. Hemicrania continua is considered a primary headache disorder, meaning that another condition does not cause it.

<span class="mw-page-title-main">Tolosa–Hunt syndrome</span> Medical condition

Tolosa–Hunt syndrome is a rare disorder characterized by severe and unilateral headaches with orbital pain, along with weakness and paralysis (ophthalmoplegia) of certain eye muscles.

Geniculate ganglionitis or geniculate neuralgia (GN), also called nervus intermedius neuralgia, Ramsay Hunt syndrome, or Hunt's neuralgia, is a rare disorder characterized by severe paroxysmal neuralgic pain deep in the ear, that may spread to the ear canal, outer ear, mastoid or eye regions. GN may also occur in combination with trigeminal or glossopharyngeal neuralgia.

Paroxysmal extreme pain disorder originally named familial rectal pain syndrome, is a rare disorder whose most notable features are pain in the mandibular, ocular and rectal areas as well as flushing. PEPD often first manifests at the beginning of life, perhaps even in utero, with symptoms persisting throughout life. PEPD symptoms are reminiscent of primary erythromelalgia, as both result in flushing and episodic pain, though pain is typically present in the extremities for primary erythromelalgia. Both of these disorders have recently been shown to be allelic, both caused by mutations in the voltage-gated sodium channel NaV1.7 encoded by the gene SCN9A. A different mutation in the SCN9A ion channel causes congenital insensitivity to pain.

<span class="mw-page-title-main">Atypical trigeminal neuralgia</span> Medical condition

Atypical trigeminal neuralgia (ATN), or type 2 trigeminal neuralgia, is a form of trigeminal neuralgia, a disorder of the fifth cranial nerve. This form of nerve pain is difficult to diagnose, as it is rare and the symptoms overlap with several other disorders. The symptoms can occur in addition to having migraine headache, or can be mistaken for migraine alone, or dental problems such as temporomandibular joint disorder or musculoskeletal issues. ATN can have a wide range of symptoms and the pain can fluctuate in intensity from mild aching to a crushing or burning sensation, and also to the extreme pain experienced with the more common trigeminal neuralgia.

Hypnic headaches are benign primary headaches that affect the elderly, with an average age of onset at 63 ± 11 years. They are moderate, throbbing, bilateral or unilateral headaches that wake the sufferer from sleep once or multiple times a night. They typically begin a few hours after sleep begins and can last from 15–180 min. There is normally no nausea, photophobia, phonophobia or autonomic symptoms associated with the headache. They commonly occur at the same time every night possibly linking the headaches with circadian rhythm, but polysomnography has recently revealed that the onset of hypnic headaches may be associated with REM sleep.

<span class="mw-page-title-main">Mollaret's meningitis</span> Medical condition

Mollaret's meningitis is a recurrent or chronic inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges. Since Mollaret's meningitis is a recurrent, benign (non-cancerous), aseptic meningitis, it is also referred to as benign recurrent lymphocytic meningitis. It was named for Pierre Mollaret, the French neurologist who first described it in 1944.

The paroxysmal dyskinesias (PD) are a group of movement disorders characterized by attacks of hyperkinesia with intact consciousness. Paroxysmal dyskinesia is a rare disorder, however the number of individuals it affects remains unclear. There are three different subtypes of PD that include paroxysmal kinesigenic dyskinesia (PKD), paroxysmal nonkinesigenic dyskinesia (PNKD), and paroxysmal exercise-induced dyskinesia (PED). Other neurological diseases have similar symptoms to PD, such as epilepsy and Parkinson's. The different subtypes make accurate and quick diagnosis of PD challenging. Thus, PD is often under reported and misdiagnosed, making it difficult to accurately study its prevalence in human populations. Onset of PD is usually in late childhood to early adolescence. New drug regimens help treat symptoms of PD, but no cure for the disorder is known.

The NIH classification of headaches consists of brief, relatively vague glossary-type definitions of a limited number of headaches.

Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing is a rare headache disorder that belongs to the group of headaches called trigeminal autonomic cephalalgia (TACs). Symptoms include excruciating burning, stabbing, or electrical headaches mainly near the eye and typically these sensations are only on one side of the body. The headache attacks are typically accompanied by cranial autonomic signs that are unique to SUNCT. Each attack can last from five seconds to six minutes and may occur up to 200 times daily.

Idiopathic childhood occipital epilepsy of Gastaut (ICOE-G) is a pure but rare form of idiopathic occipital epilepsy that affects otherwise normal children and adolescents. It is classified amongst benign idiopathic childhood focal epilepsies such as rolandic epilepsy and Panayiotopoulos syndrome.

Abdominal migraine(AM) is a functional disorder that usually manifests in childhood and adolescence, without a clear pathologic mechanism or biochemical irregularity. Children frequently experience sporadic episodes of excruciating central abdominal pain accompanied by migrainous symptoms like nausea, vomiting, severe headaches, and general pallor. Abdominal migraine can be diagnosed based off clinical criteria and the exclusion of other disorders.

Trigeminal autonomic cephalalgia (TAC) refers to a group of primary headaches that occurs with pain on one side of the head in the trigeminal nerve area and symptoms in autonomic systems on the same side, such as eye watering and redness or drooping eyelids.

References

  1. 1 2 3 Butticè, Claudio (2022). What you need to know about headaches. Santa Barbara, California: Greenwood Publishing Group. ISBN   978-1-4408-7531-1. OCLC   1259297708.
  2. 1 2 3 4 Goadsby, Peter J., Stephen D. Silberstein, and David Dodick. "Chronic Paroxysmal Hemicrania". Chronic Daily Headache for Clinicians. Hamilton, Ont.: BC Decker, 2005. N. pag. Print.
  3. 1 2 3 4 Eadie, Mervyn J. "Chronic Paroxysmal Hemicrania". Headache: Through the Centuries. New York: Oxford UP, 2012. 222-24. Print.
  4. "Michigan Headache and Neurological Institute - Chronic Paroxysmal Hemicrania" . Retrieved 19 March 2014.
  5. Boes, Christopher J.; Swanson, Jerry W.; Dodick, David W. (1998). "Chronic Paroxysmal Hemicrania Presenting as Otalgia With a Sensation of External Acoustic Meatus Obstruction: Two Cases and a Pathophysiologic Hypothesis". Headache: The Journal of Head and Face Pain. 38 (10): 787–791. doi: 10.1046/j.1526-4610.1998.3810787.x . ISSN   1526-4610. PMID   11279905. S2CID   39787599.
  6. Lambru, Giorgio; Miller, Sarah; Matharu, Manjit S (2013). "The red ear syndrome". The Journal of Headache and Pain. 14 (1): 83. doi: 10.1186/1129-2377-14-83 . ISSN   1129-2369. PMC   3850925 . PMID   24093332.
  7. Mehta, Noshir R., George E. Maloney, Dhirendra S. Bana, and Steven J. Scrivani. "Head, Face, and Neck Pain: Science, Evaluation, and Management: An Interdisciplinary Approach". Hoboken, NJ: Wiley, 2009. Print.
  8. 1 2 "IHS - Chronic Paroxysmal Hemicrania". Archived from the original on 21 September 2013. Retrieved 19 March 2014.
  9. 1 2 Jay, Gary W. The Headache Handbook: Diagnosis and Treatment. Boca Raton: CRC, 1998. Print.
  10. Pareja, Ja, Ab Caminero, E. Franco, Jl Casado, J. Pascual, and M. Sanchez Del Ri'o. "Dose, Efficacy and Tolerability of Long-term Indomethacin Treatment of Chronic Paroxysmal Hemicrania and Hemicrania Continua". Cephalalgia. 21.9 (2001): 906-10. Print.
  11. Camarda, Cecilia, Rosolino Camarda, and Roberto Monastero. "Chronic Paroxysmal Hemicrania And Hemicrania Continua Responding To Topiramate: Two Case Reports". Clinical Neurology & Neurosurgery. 100.1 (2008): 88-91. Academic Search Complete. Web. 27 Feb. 2014.
  12. Milanlioglu, A., T. Tombul, and R. Sayin. "Chronic Paroxysmal Hemicrania Responsive to Lamotrigine". Pakistan Journal of Medical Sciences. 27.2 (2011): 456-57. Web.
  13. "The Migraine Trust - Paroxysmal Hemicrania". Archived from the original on 24 March 2014. Retrieved 20 March 2014.
  14. 1 2 "Medscape - Chronic Paroxysmal Hemicrania" . Retrieved 20 March 2014.